A Phase 1 interventional study of VEGF Trap and VEGF Trap in Neovascular Age Related Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-04-21.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 67 studies testing aflibercept in Macular Degeneration, this one is the 61st largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 1, and was the 3rd registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Honghua Yu,MD
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 28
First in 2005; this study’s year is marked. 2 started in 2006.
This study's enrollment of 20 is below the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 54 across the 67 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 67 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
17 studies in Macular Degeneration by Regeneron Pharmaceuticals: 2 open now, 3 under way, 2 of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 17 studies in Macular Degeneration by Regeneron Pharmaceuticals, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 1, and was the 3rd registered.
Regeneron Pharmaceuticals’s Macular Degeneration studies by the year they started, since 2005.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 67 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Regeneron Pharmaceuticals’s 17 in Macular Degeneration:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the safety and tolerability of repeated intravitreal (ITV) administration of VEGF Trap.
A double-masked study in which approximately 12 subjects will receive ITV injections of VEGF Trap every 4 weeks for a total of 3 doses. Once the subjects have received the 3 doses allowed in this study, they will be evaluated every 4 weeks for continued dosing of VEGF Trap for an additional 9 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No prior treatment with the following in the study eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VEGF Trap formulation 1
Drug: VEGF Trap
VEGF Trap formulation 2
Drug: VEGF Trap
VEGF Trap formulation 2 open label, higher concentration
Biological: VEGF Trap
The primary endpoint of the study will be safety and tolerability of the study treatment at Week 12 as assessed by ophthalmic examination and reporting of AEs.
Time frame: 12 weeks
The record gives a start of Oct 2006, a primary completion of Sep 2007 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept